The relationship between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS) is a controversial area of research. Correction of CCSVI in patients with MS has been attempted using percutaneous venoplasty. The intent of this procedure, sometimes referred to as the ‘Liberation Procedure’, is to relieve MS symptoms by improving venous drainage of the central nervous system.
The foundation of this vascular theory is that there is abnormal venous drainage from the brain due to outflow obstruction in the draining jugular vein and/or azygos veins. This abnormal venous drainage, which is identified by special ultrasound criteria, is said to cause intracerebral flow disturbance or outflow problems that lead to periventricular deposits. In the CCSVI theory, these deposits have a similarity to the iron deposits seen around the veins in the legs in individuals with chronic deep vein thrombosis. Those studying this theory have promoted the idea that balloon dilatation, with or without stenting, will resolve the CCSVI and alleviate MS complaints.
The diagnosis and subsequent treatment of chronic cerebrospinal venous insufficiency in individuals with multiple sclerosis is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
The association between CCSVI and MS, especially as a causative factor, remains unclear. The evidence is insufficient to determine the effects of the technology on health outcomes.
Baracchini, C., Valdueza, J. M., Del Sette, M., Baltgaile, G., Bartels, E., Bornstein, N. M., et al. (2012). CCSVI and MS: A statement from the European Society of neurosonology and cerebral hemodynamics. Journal of Neurology, 259 (12), 2585-2589. (Level 2 evidence)
Costello, F., Modi, J., Lautner, D., Bhayana, D., Scott, J., Davenport, W., et al. (2014). Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. Canadian Medical Association Journal, 186 (11), E418-E426. (Level 3 evidence)
Kugler, N., Patel, P., & Lee, C. (2015). Chronic cerebrospinal venous insufficiency in multiple sclerosis: a failed concept. Vascular Specialist International, 31 (1), 11-14. (Level 3 evidence)
National Institute for Health and Clinical Excellence (NICE). (2012). Percutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis. Retrieved November 4, 2013 from http://www.nice.org.
Siddiqui, A., Zivadinov, R., Karmon, Y., Yu, J., Hartney, M., Marr, K., et al. (2014). Prospective randomized trial of venous angioplasty in MS (PREMiSe) Neurology, 83, 441-449. (Level 1 evidence)
Tsivgoulis, G., Faissner, S., Voumvourakis, K., Katsanos, A., Triantafyllou, N., Grigoriadis, N. (2015). “Liberation treatment” for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior, 5 (1), 3-12. (Level 2 evidence)
U. S. Food and Drug Administration. (2012, May). U. S. Department of Health and Human Services. FDA safety communication: Chronic cerebrospinal venous insufficiency treatment in multiple sclerosis patients. Retrieved May 14, 2012 from http://www.fda.gov.
Zivadinov, R., Karmon, Y., Dolic, K., Hagemeier, J., Marr, K., Valnarov, V., et al. (2013). Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study. BMC Neurology, 13, 151. (Level 2 evidence)
ORIGINAL EFFECTIVE DATE: 7/14/2012
MOST RECENT REVIEW DATE: 1/10/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.